DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 20415 / S-023 / S-024
NDA 21208 / S-013 / S-014

SUPPLEMENT APPROVAL

Organon USA Inc.
Attention: Dori L. Glassner
Director and Liaison, Global Regulatory Affairs
200 Galloping Hill Road
Kenilworth, NJ 07033

Dear Ms. Glassner:

Please refer to your Supplemental New Drug Applications dated December 23, 2010, received December 24, 2010 (NDA 20415 / S-023 and NDA 21208 / S-013). Refer also to your Supplemental New Drug Applications dated March 5, 2010, received March 8, 2010 (NDA 20415 / S-024 and NDA 21208 / S-014), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Remeron (mirtazapine) 15mg, 30mg, and 45mg Tablets and RemeronSolTab (mirtazapine) Orally Disintegrating 15mg, 30mg, and 45mg Tablets.

Supplements S-023 and S-013, submitted as "Prior Approval," provide for changes to the labeling regarding concomitant use with monoamine oxidase inhibitors, serotonin syndrome, discontinuation symptoms, akathisia/psychomotor restlessness, hyponatremia, cytochrome P450 enzyme inhibition/induction, other drug-drug interactions, switching patients to or from a monoamine oxidase inhibitor, and discontinuation of Remeron treatment. Each product Medication Guide has also been amended to reflect these changes.

Supplements S-024 and S-014, submitted as "Prior Approval," provide for the addition of the following statement as the last sentence under the **ADVERSE REACTIONS, Other Adverse Events Observed During Postmarketing Evaluation of REMERON** subsection of the package insert:

> "Cases of severe skin reactions, including Stevens-Johnson Syndrome, bullous dermatitis, erythema multiforme and toxic epidermal necrolysis have also been reported."

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text and with minor editorial revisions (correction of misspellings and abbreviations).

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical to the enclosed labeling (text for the package insert, Medication Guide) and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including pending "Changes Being Effected" (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format that includes the changes approved in these supplemental applications.

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

All promotional materials for your drug product that include representations about your drug product must be promptly revised to make it consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions to your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

As required under 21 CFR 314.81(b)(3)(i), you must submit your updated final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA-2253, directly to the above address. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

LETTERS TO HEALTH CARE PROFESSIONALS

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA, to CDERMedWatchSafetyAlerts@fda.hhs.gov, and to the following address:

MedWatch
Food and Drug Administration
Suite 12B-05
5600 Fishers Lane
Rockville, MD 20857

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, email Hiren Patel, Pharm.D., Regulatory Project Manager, at Hiren.Patel@FDA.HHS.GOV.

Sincerely,

{See appended electronic signature page}

Thomas Laughren, M.D.
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURES:
Content of Labeling

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
NDA-21208	SUPPL-14	ORGANON USA INC	REMERON SOL TAB(MIRTAZAPINE)15/30/45MG
NDA-21208	SUPPL-13	ORGANON USA INC	REMERON SOL TAB(MIRTAZAPINE)15/30/45MG
NDA-20415	SUPPL-24	ORGANON USA INC	REMERON (MIRTAZAPINE) 15MG/30MG TABLETS
NDA-20415	SUPPL-23	ORGANON USA INC	REMERON (MIRTAZAPINE) 15MG/30MG TABLETS

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

THOMAS P LAUGHREN
05/14/2010